Effect of clinical events on plasma HIV-1 RNA levels in persons with CD4+ T-lymphocyte counts of more than 500 x 106 cells/l

AIDS

Volumn 14, Issue 9, 2000, Pages 1135-1146

  Chapman, Louisa E ^a,e   Green, Timothy A ^e   Ahmed, Farhad ^a   Parekh, Bharat S ^b   Rimland, David ^c   Kaplan, Jonathan E ^e   Thompson, Melanie A ^d   Folks, Thomas M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d AIDS Research Consortium of Atlanta   (United States)

^e NONE

Author keywords

HIV 1 infection; Immune activation; Immunizations; Infections; Plasma viral load

Indexed keywords

VIRUS RNA;

ADULT; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOSTIMULATION; INFECTION; INTERVIEW; LYMPHOCYTE COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0033919662     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00010     Document Type: Article

References (45)

1. 1. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:529-533.
2. 2. Vidal C, Garcia F, Romeu J, et al. Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection. AIDS 1998, 12:1285-1289.
3. 3. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1 , even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
4. 4. McCune JM. Viral latency in HIV disease. Cell 1995, 82: 183-188.
5. 5. Michael NL, Chang G, Kim JH, Birx DL. Dynamics of cell-free viral burden in HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:237-242.
6. 6. Folks TM, Powell DM, Lightfoote MM, Benn S, Martin MA, Fauci AS. Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science 1986, 231:600-602.
7. 7. Butera ST, Roberts BD, Lam L, Hodge T, Folks TM. Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency. J Virol 1994, 68:2726-2730.
8. 8. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. Science 1989, 243:355-361.
9. 9. Stanley SH, Ostrowski MA, Justment JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1229.
10. 10. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993, 262:1011-1018.
11. 11. Folks TM, Kelly J, Benn S, et al. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol 1986, 136:4049-4053.
12. 12. Coffin JM. HIV Population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
13. 13. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
14. 14. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997, 387:188-191.
15. 15. Spina CA, Guateli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1-DNA in quiescent CD4 lymphocytes in vitro. J Virol 1995, 69: 2977-2988.
16. 16. Folks TM, Clouse KA, Justement J, et al. Tumor necrosis factor à induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989, 86:2365-2368.
17. 17. Ostrowski MA, Stanley SK, Justement JS, Gantt K, Goletti D, Fauci AS. Increased in vitro tetanus-induced production of HIV type 1 following in vivo immunization of HIV type 1-infected individuals with tetanus toxoid. AIDS Res Hum Retroviruses 1997, 13:473-480.
18. 18. Coletti D, Weissman D, Jackson RW, et al. Effect of mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996, 157:1271-1278.
19. 19. Folks TM, Rowe T, Villinger F, et al. Immune stimulation may contribute to enhanced progression of SIV induced disease in rhesus macaques. J Med Primatol 1997, 26:181-189.
20. 20. Sousa AO, Lee FK, Freiji R, Lagrange PH, Nahmias A. Human immunodeficiency virus infection alters antigen-induced cytokine responses in patients with active mycobacterial diseases. J Infect Dis 1998, 177:1554-1562.
21. 21. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dormant factor in the pathogenesis of African AIDS. Immunol Today 1995, 16:187-191.
22. 22. Lui Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:332-340.
23. 23. Anzala OA, Nagelkerke NJD, Bwayo JJ, et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995, 171:686-689.
24. 24. O Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus type-1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995, 86:1082-1089.
25. 25. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J Exp Med 1995, 182:1727-1737.
26. 26. Ortigao-de-Sampaio MB, Shattock RJ, Hayes P, et al. Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS 1998, 12:F145-F150.
27. 27. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996, 174:1191-1199.
28. 28. Ho DD. HIV-1 viremia and influenza [letter]. Lancet 1992, 339:1549.
29. 29. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravoiatz LD. Changes in virus load markers during AIDS-Associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996, 174:401-403.
30. 30. Bush CE, Donovan RM, Markowitz NP, Kvale P, Saravolatz LD. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:23-26.
31. 31. Jackson CR, Vavro CL, Valentine ME, et al. Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr Infect Dis J 1997, 16:200-204.
32. 32. Bodsworth NJ, Neilsen GA, Donovan B. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up. AIDS 1997, 11:747-749.
33. 33. Yerly S, Wunderli W, Wyler CA, et al. Influenza immunization of HIV-1 infected patients does not increase HIV-1 viral load. AIDS 1994, 8:1503-1504.
34. 34. Ramilo O, Hicks PJ, Borvak J, et al. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J 1996, 15:197-203.
35. 35. Cheeseman SH, Davaro RE, Ellison RT III. Hepatitis B vaccination and plasma HIV-1 RNA. New Engl J Med 1996, 334:1272.
36. 36. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of Influenza vaccinations on human immunodeficiency virus type 1 load: a randomized, double-blind, placebocontrolled study. J Infect Dis 1996, 174:1332-1336.
37. 37. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997, 176:766-770.
38. 38. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, Quinn TC. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 1998, 178:1642-1648.
39. 39. Marchisio P, Esposito S, Zanchetta N, Tornaghi R, Gismondo MR, Principi N. Effect of superimposed infections on viral replication in Human Immunodeficiency Virus Type 1-infected children. Pediatr Infect Dis J 1998, 17:755-757.
40. 40. Pedneault L, Lapointe N, Alfieri C, et al. Natural history of Epstein-Barr virus infection in a prospective pediatric cohort born to human immunodeficiency virus-infected mothers. J Infect Dis 1998, 177:1087-1090.
41. 41. Rosok B, Voltersvik P, Bjerknes R, Axelsson M, Haaheim LR, Asjo B. Dynamics of HIV-1 replication following influenza vaccination of HIV+ individuals. Clin Exp Immunol 1996, 104:203-207.
42. 42. Paul WE. Can the immune response control HIV infection? Cell 1995, 82:177-182.
43. 43. Coffin JM. HIV dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
44. 44. Fowke KR, D Amico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination on HIV-1 infected patients. AIDS 1997, 11:1013-1021.
45. 45. Grossman Z, Herberman RB. T-cell homeostasis in HIV infection is neither failing nor blind: modified cell counts reflect an adaptive response of the host. Nat Med 1997, 3:486-490.